ESTHER RIAMBAU
CEO
ONIRIA THERAPEUTICS, S.L.
Barcelona, España
42 visitas al perfilParticipante
Oniria Therapeutics desarrolla ONR-001, first-in-class en oncología de precisión contra la recurrencia tumoral, con eficacia y seguridad preclínica demostradas
Mi organización
Oniria Therapeutics, a company from the precision oncology field, wants to solve cancer persistence by bringing to the market the first-in-class drug ONR-001, for the treatment of solid and liquid aggressive tumors who are not responding to treatment, setting the base for new rational drug combinations or standing alone treatments.
Acerca de mí
Habilidades
- oncology
- cancer
- melanoma
- Colorectal cancer
- Therapeutic
- epigenetic drug
- Biomarker
- acute myeloid leukemia
- Drug discovery
- allosterical activation
- TET2 target
- neurodegenerative diseases
- biopharmaceutical company
Intereses
- collaboration agreement
- codevelopment
- Investment
- Series A
- licensing-out
Preguntas adicionales
Organization category
Biotech - Therapeutics and Diagnostics